Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Heart Failure
Interventions
DRUG

Anakinra (high dose)

Anakinra 100 mg daily twice daily for days 1, 2, and 3

DRUG

Anakinra (standard dose)

Anakinra 100 mg daily for days 4-14

DRUG

Placebo

Placebo twice daily for days 1, 2, and 3

DRUG

Placebo

Placebo daily for days 4-14

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Virginia Commonwealth University

OTHER

NCT01936844 - Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF) | Biotech Hunter | Biotech Hunter